Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment
Poorly controlled hypertension as assessed by the investigator
History of Acute Myeloid Leukemia (AML) or high risk for AML
Administration of another investigational drug within 1 month before screening or planned during the study period
Previously documented evidence of Pure Red Cell Aplasia (PRCA)

NCT02145026_exc_T1
Condition
Contraindications
NCT02145026_exc_T2
Condition
hypersensitivity
NCT02145026_exc_T3
Procedure
epoetin beta treatment
NCT02145026_exc_T4
Scope
Contraindications and/or known hypersensitivity
NCT02145026_exc_T5
Condition
hypertension
NCT02145026_exc_T6
Qualifier
Poorly controlled
NCT02145026_exc_T7
Condition
Acute Myeloid Leukemia
NCT02145026_exc_T8
Condition
AML
NCT02145026_exc_T9
Observation
risk for AML
NCT02145026_exc_T10
Qualifier
high
NCT02145026_exc_T12
Condition
Pure Red Cell Aplasia
NCT02145026_exc_T13
Condition
PRCA